[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-362161-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-362161-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","lipid-metabolism-reprograming-by-srebp1-pcsk9-targeting-sensitizes-pancreatic-cancer-to-immunochemotherapy","Lipid metabolism reprograming by SREBP1-PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy","","Pancreatic ductal adenocarcinoma exhibits aberrant lipid metabolism that supports tumor growth, invasion, and metastasis, while its effects on immune surveillance and response to immunotherapy remain uncertain. This study evaluates how SREBP1-driven lipid metabolism reshapes the tumor microenvironment (TME) in PDAC, assessing clinical relevance of SREBP1 in China and TCGA cohorts. The work integrates mechanistic analyses of SREBP1-PCSK9 targeting and explores immunochemotherapy sensitization outcomes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/lipid-metabolism-reprograming-by-srebp1-pcsk9-targeting-sensitizes-pancreatic-cancer-to-immunochemotherapy/362161/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/lipid-metabolism-reprograming-by-srebp1-pcsk9-targeting-sensitizes-pancreatic-cancer-to-immunochemotherapy/362161.png","ImageObject",300,407,{"name":42,"@type":43},"Miles","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does the study describe pancreatic cancer lipid metabolism in PDAC?","Question",{"text":63,"@type":64},"It describes aberrant lipid metabolism as a driver of cell growth, invasion, and metastasis in PDAC, while emphasizing uncertainty about how it influences immune surveillance and immunotherapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is the central biological focus of the research?",{"text":68,"@type":64},"The research centers on how SREBP1-driven lipid metabolism affects the tumor microenvironment (TME) and how SREBP1-PCSK9 targeting may sensitize pancreatic cancer to immunochemotherapy.",{"name":70,"@type":61,"acceptedAnswer":71},"How was clinical relevance evaluated in the study?",{"text":72,"@type":64},"Clinical significance of SREBP1 was assessed using PDAC cohorts from China and The Cancer Genome Atlas (TCGA) cohorts.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},362161,1790919727,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","DOI: 10.1002/cac2.70038  \nORIGINAL ARTICLE  \nLipid metabolism reprograming by SREBP1-PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy  \nMengyi Lao1,2, 3,4  Hanshen Yang1,2, 3 Hanjia Zhang1,2, 3  \n Xiaozhen Zhang1,2, 3  Zejun Li1,2, 3  Kang Sun1,2, 3  Sicheng Wang1, 2, 3  Lihong He1,2, 3  Yan Chen1,2, 3  Jiatao Shi1,2, 3  Daqian Xu1,2, 5  Tingbo Liang1,2, 3   \nXueli Bai1,2, 3   \n1 Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, P.  \nR. China  \n2Zhejiang Provincial Key Laboratory of Pancreatic Disease, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China  \n3 Cancer Center, Zhejiang University, Hangzhou, Zhejiang, P. R. China  \n4 Department of Breast Surgery, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China  \n5 Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China  \nList of Abbreviations: ACACA, acetyl-CoA carboxylase alpha; ACSL1, acyl-CoA synthetase long-chain family member 1; ACTB, β-actin; ANOVA, Analysis of Variance; AUC, Area under the curve; Baf-A1, bafilomycin-A1; BCA, bicinchoninic acid; CAF, cancer-associated fibroblast; CCK-8, cell counting kit-8.; CD, chow diet; CFDA, China Food and Drug Administration; ChIP, chromatin immunoprecipitation; CHX, cycloheximide; CMV, cytomegalovirus; Co-IP, Co-immunoprecipitation; CTLA4, cytotoxic T-lymphocyte associated protein 4; CUT & Tag, Cleavage Under Targets and Tagmentation; DAPI, 2- (4-Amidinophenyl)-6-indolecarbamidine dihydrochloride; DDT, dithiothreitol; DMEM, Dulbecco’s modified Eagle’s medium; ELISA, enzyme-linked immunosorbent assay; FABP4, fatty acid-binding protein 4; FASN, fatty acid synthase; FBS, fetal bovine serum; FC, fold change; Foxp3, forkhead box P3; FPKM, fragments per kilobase of exon model per million mapped fragments; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GC-MS, gas chromatography-mass spectrometry; GEM, gemcitabine; GEMM-KTC,  \nLSL-KrasG12D/+;TgfbRfl/+; Ptfla-cre driven spontaneous PDAC ; GO, gene ontology; GSEA, Gene Set Enrichment Analysis; GST, glutathione S-transferase; GZMB, granzyme B; HDL, high-density lipoprotein; HFD, high-fat diet; HIF-1; NF-κB, hypoxia inducible factor-1; nuclear factor kappa-B; IAA, iodoacetamide; ICB, Immune checkpoint blockade; IF, immunofluorescence; IFN-γ, interferon gamma; IHC, immunohistochemistry analysis; IL-2, interleukin 2; IQR, interquartile range; KEGG, Kyoto Encyclopedia of Genes and Genomes; KPC, LSL-KrasG12D/+; LAMP2, lysosome-associated membrane protein 2; LC, liquid chromatography; LDL, low-density lipoprotein; LSL-Trp53R172H/+, ; mAbs, monoclonal antibodies; MGST1, microsomal glutathione  \nS-transferase 1; MHC-I, major histocompatibility complex class I; mIHC, multiplexed IHC; MS, mass spectrometry; MSigDB, molecular signatures; OE, overexpression; OPLS-DA, orthogonal partial least-squares discriminant analysis; OS, overall survival; pan-CK, pan Cytokeratin; PBS, phosphate-buffered saline; PCA, principal component analysis; PCSK9, proprotein convertase subtilisin/kexin type 9; PD-1, programmed death receptor 1; PDAC, pancreatic ductal adenocarcinoma; PD-L1, programmed cell death 1 ligand 1; PDX, patient-derived xenograft; , Pdx1-Cre; , Ptfla-cre driven spontaneous PDAC; PVDF, polyvinylidene fluoride; qRT-PCR, quantitative reverse transcription polymerase chain reaction; RECIST, Response Evaluation Criteria in Solid Tumors version 1.1; RIPA, radioimmunoprecipitation assay; RNA-Seq, RNA-sequencing; ROC, receiver operating characteristic; SCAP, SREBP cleavage activating protein; SCD1, stearoyl-CoA desaturase 1; SD, standard deviation; shRNAs, short hairpin RNAs; siRNAs, small interfering RNAs; SPF, specific pathogen-free; SREBF1, sterol regulatory element binding transcription factor 1; SREBP1, sterol regulatory element binding prote","cbCaihzq0oRkl9fb","https://ap.wps.com/l/cbCaihzq0oRkl9fb","pdf",5992716,28,"English","# Abstract\n## Background\n## Methods","[{\"question\":\"How does the study describe pancreatic cancer lipid metabolism in PDAC?\",\"answer\":\"It describes aberrant lipid metabolism as a driver of cell growth, invasion, and metastasis in PDAC, while emphasizing uncertainty about how it influences immune surveillance and immunotherapy.\"},{\"question\":\"What is the central biological focus of the research?\",\"answer\":\"The research centers on how SREBP1-driven lipid metabolism affects the tumor microenvironment (TME) and how SREBP1-PCSK9 targeting may sensitize pancreatic cancer to immunochemotherapy.\"},{\"question\":\"How was clinical relevance evaluated in the study?\",\"answer\":\"Clinical significance of SREBP1 was assessed using PDAC cohorts from China and The Cancer Genome Atlas (TCGA) cohorts.\"}]","Lipid metabolism reprograming by SREBP1-PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy | PDF",1790146621,71,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d449498e8e52867173191ab991a70362.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d293804d46f1b7ecee5466de16de42bf.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e60b195bdb54e8735e433a2c85b817f6.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9290a9c428e67e77c0736691e16f1731.webp",980,1287]